Sign in

You're signed outSign in or to get full access.

TB

TELA Bio, Inc. (TELA)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 revenue was $17.6M with gross margin of 64%; sequentially lower vs Q3 ($19.0M) due to sales force attrition and elective surgery disruptions tied to IV fluid shortages from Hurricane Helane; FY24 revenue reached $69.3M (+19% y/y) but missed previously reiterated FY24 guidance ($74.5–$76.5M) .
  • Net loss improved year over year in Q4 to $(9.2)M vs $(12.9)M; Q4 diluted EPS was $(0.23), better than $(0.53) in Q4 2023, reflecting OpEx cuts implemented in Q3 that continued into Q4 .
  • FY25 guidance: revenue $85–$88M (+23–27% y/y), Q1 2025 revenue $17–$18M (+2–8% y/y), and OpEx flat vs 2024; management expects normalized growth with rebuilt sales capacity and portfolio expansion (larger PRS sizes, long-term resorbable hernia product) .
  • Near-term catalysts: sales force rebuild and compensation plan changes, growing adoption of OviTex IHR and LIQUIFIX, and IDE approval for PRS resorbable breast reconstruction study; strengthened liquidity after October 2024 equity offering (gross proceeds ~$46M) supported YE cash of $52.7M .

What Went Well and What Went Wrong

What Went Well

  • Record FY24 revenue (+19% y/y) with full-year OviTex unit sales +33% and OviTex PRS +31%; Q4 net loss and opex improved vs prior year due to efficiency measures .
  • Portfolio momentum: OviTex IHR sold >1,200 units since April 2024 launch; LIQUIFIX sales nearing $1M; 2025 launches planned (larger PRS sizes; long-term resorbable hernia) .
  • Strategic positioning: management emphasized long-term tailwinds from market shift away from permanent synthetic mesh and alternatives to cadaveric tissue in PRS. “We are optimistic about TELA’s outlook… restore topline growth… continue our steady path towards profitability.” .

What Went Wrong

  • Q4 growth slowed to low single digits (+4% y/y) and sequential decline vs Q3 amid lower-than-planned sales headcount and 11 unplanned TM departures in Nov–Dec; top 44 reps still performed ≥90% to quota, highlighting uneven coverage .
  • External headwinds: hurricane-related IV fluid shortages reduced elective volumes in TELA’s two strongest Southeast regions, with impact most notable in Nov–Dec .
  • Mix/ASP pressure: higher share of smaller-sized units from robotic/minimally invasive procedures (IHR) pressured average selling prices; Q4 gross margin fell to 64% due to excess/obsolete inventory expense tied to new product generations .

Financial Results

MetricQ2 2024Q3 2024Q4 2024
Revenue ($USD Millions)$16.091 $18.957 $17.649
Gross Profit ($USD Millions)$11.073 $12.858 $11.221
Gross Margin %69% 68% 64%
Operating Expenses ($USD Millions)$22.643 $22.223 $19.575
Loss from Operations ($USD Millions)$(11.570) $(9.365) $(8.354)
Net Loss ($USD Millions)$(12.600) $(10.372) $(9.208)
Diluted EPS ($USD)$(0.51) $(0.42) $(0.23)
Product Unit Sales Growth (YoY %)Q2 2024Q3 2024Q4 2024
OviTex Units GrowthN/A+39% +28%
OviTex PRS Units GrowthN/A+44% +11%
KPIsQ2 2024Q3 2024Q4 2024
Cash & Equivalents ($USD Millions)$26.496 $17.301 $52.670
Field-based sales force (TMs + ASs)86 + 6 69 + 7 63 + 8
OviTex IHR cumulative unitsN/AN/A>1,200
Estimates vs Actuals (Q4 2024)ConsensusActual
Revenue ($USD Millions)Unavailable (SPGI API limit)$17.649
Diluted EPS ($USD)Unavailable (SPGI API limit)$(0.23)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueFY 2024$74.5–$76.5M Actual: $69.3M Missed vs prior guidance
RevenueFY 2025N/A$85.0–$88.0M New
RevenueQ1 2025N/A$17.0–$18.0M (+2–8% y/y) New
Operating ExpensesFY 2025Reduce OpEx in 2025 by $5–$10M vs annualized H1’24 run rate Flat vs 2024 Efficiency posture maintained; framing updated

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 2024)Previous Mentions (Q3 2024)Current Period (Q4 2024)Trend
Sales force realignment & attritionNew CCO; programs to improve training, supervision, accountability OpEx efficiency improvements; rep mix evolved (69 TMs + 7 associates) 11 unplanned TM departures Nov–Dec; end-Q4 63 TMs + 8 ASs; rebuilding to ~97 field reps in 2025 (70+ TMs, ~20 ASs) Disruption in Q4, rebuild underway
External headwinds (cyber, IV fluids)Ransomware at GPO and separate hospital cyber event reduced surgeries Noted IV fluid shortages may affect outlook unpredictably IV fluid plant damage from Hurricane Helane; elective procedures slowed in strongest regions; shortages hit Nov–Dec Easing; viewed as transient
Product performance/launchesLaunched OviTex IHR; NIVIS revenue share starting Q3 Record quarterly revenue; portfolio strengthening >1,200 IHR units since Apr-2024; LIQUIFIX near $1M; 2025 launches: larger PRS, long-term resorbable hernia Expanding portfolio drives reach
Pricing/mix & ASPMix shift toward smaller units from IHR/robotic Mix reduced ASPs; growth driven by units ASP dilution in hernia from smaller pieces; PRS ASP potentially stable to growing (larger LTR pieces) Balanced by volume growth
Clinical/R&D execution——IDE approval for PRS resorbable breast reconstruction study; OPERA enrollment; 300–400 PRS patients by YE25 Evidence base expanding
Market narrative—Shift away from permanent synthetics; robotics opportunity (investor deck) Management reiterates tailwinds from shift away from permanent synthetics and alternatives to cadaveric tissue Favorable structural tailwinds

Management Commentary

  • “Our fourth quarter results fell short of our expectations due to a confluence of disruptions… we have taken necessary steps to drive additional market share capture… restore topline growth … and continue our steady path towards profitability.” — Antony Koblish, CEO .
  • Primary Q4 underperformance driver: “lower-than-planned head count in our U.S. sales force… [with] unplanned productive losses in late November and into December,” plus hurricane-driven IV fluid shortages impacting elective procedures .
  • Sales rebuild plan: target ~97 field reps in 2025; team-based TM+AS sales model to enhance coverage and retention; compensation plan revamped with near-quota payouts and stretch goal upside to deter poaching .
  • Portfolio momentum and pipeline: “We expect to launch larger-sized versions of our existing OviTex PRS products and a new long-term resorbable alternative for our hernia products” in 2025 .
  • Evidence and studies: IDE approved for PRS resorbable breast reconstruction; OPERA study enrollment continues; aim for 300–400 PRS patients in studies by YE25 .

Q&A Highlights

  • Rep attrition details: 11 TM departures in Nov–Dec; mid-to-upper tier performers poached by wound care and PRS entrants; backfilling underway with AS support and talent upgrades .
  • Volume vs ASP dynamics: hernia portfolio mix shift toward smaller pieces (IHR/robotic) dilute ASP; PRS ASP likely stable/higher with larger LTR pieces; both incremental (non-cannibalistic) .
  • Profitability confidence: OpEx expected flat in 2025 vs 2024; operating efficiency improvements extend from 2H24; management confident existing liquidity is sufficient to reach profitability .
  • Revenue cadence: expect typical seasonality (Q1 to Q2 step-up, modest Q2 to Q3 due to summer, stronger Q3 to Q4); Q1 2025 expected “as usual or better” given momentum .
  • Retention strategy: revamped comp plan (near-quota payouts, national/regional stretch goals), earlier NSM rollout, team selling to accelerate backfills and defend accounts .

Estimates Context

  • SPGI S&P Global consensus for Q4 2024 revenue and EPS and for the prior two quarters could not be retrieved at this time due to SPGI API rate limits; comparisons vs consensus are therefore unavailable.
  • For context on near-term expectations, Q1 2025 revenue consensus was ~$17.35M* vs company guidance of $17–$18M; management indicated momentum would support Q1 performance .
  • Values retrieved from S&P Global.*

Key Takeaways for Investors

  • Execution reset: The Q4 shortfall was primarily sales-force driven; the rebuild (more ASs, target ~97 reps, revised comp) is designed to stabilize growth and defend accounts, a critical near-term stock driver .
  • Mix vs margin: Greater IHR/robotic penetration drives unit volume but dilutes ASP and pressured Q4 gross margin (excess/obsolete inventory from new generations); watch margin trajectory as portfolio mix normalizes .
  • 2025 growth setup: FY25 revenue guide $85–$88M implies restored growth; delivery hinges on rep ramp speed, elective volumes normalizing, and incremental contributions from larger PRS and resorbable hernia products .
  • Liquidity and runway: October 2024 equity raise (~$46M gross) and YE cash of $52.7M extend runway to profitability; OpEx discipline (flat in 2025) supports operating leverage .
  • Structural tailwinds: Market shift away from permanent synthetics and surgeon interest in alternatives in PRS provide multi-year share capture opportunity; continued clinical evidence (IDE, OPERA) strengthens differentiation .
  • Near-term watch items: Q1 trajectory vs guide; sales headcount progression and retention; ASP mix stabilization; inventory management for new generations; cadence of surgeon education and GPO access .
  • Medium-term thesis: Scaling commercial execution with an expanding portfolio in large markets (hernia, PRS) plus operating discipline should drive progress toward the $100M revenue milestone and eventual profitability .